Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 2:03 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 1,194 matching trials from the live ClinicalTrials.gov search.
Filters: Durham, North Carolina Clear all
Completed Phase 1Phase 2 Interventional Results available

A Randomized, Double-Blind Placebo-Controlled Peanut Sublingual Immunotherapy Trial

NCT00580606
View directory record Official record
Conditions
Food Hypersensitivity, Hypersensitivity, Immediate Hypersensitivity, Peanut Hypersensitivity
Interventions
Glycerinated peanut allergenic extract, Placebo for peanut extract (glycerin)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years to 40 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
5
States / cities
Little Rock, Arkansas • Denver, Colorado • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Nov 3, 2026, 2:03 PM EST
Completed Phase 2 Interventional

A Study of CDX-0159 in Patients With Eosinophilic Esophagitis

NCT05774184
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
barzolvolimab, Matching Placebo
Biological · Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
24
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Sun City, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Nov 3, 2026, 2:03 PM EST
Recruiting No phase listed Observational

US National OCS Heart Perfusion (OHP) Registry

NCT05915299
View directory record Official record
Conditions
Heart Transplant
Interventions
OCS Heart
Device
Lead sponsor
TransMedics
Industry
Eligibility
Not listed
Enrollment
100,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
37
States / cities
Phoenix, Arizona • La Jolla, California • Palo Alto, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Nov 3, 2026, 2:03 PM EST
Completed Phase 3 Interventional Results available

Bacterial Vaginosis Home Screening to Prevent STDs

NCT00667368
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
Metronidazole
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
15 Years to 25 Years · Female only
Enrollment
1,370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
7
States / cities
Birmingham, Alabama • San Francisco, California • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2020 · Synced Nov 3, 2026, 2:03 PM EST
Recruiting Phase 3 Interventional

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

NCT06252649
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
FOLFIRI Regimen, Sotorasib, Panitumumab, Bevacizumab-awwb
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
26
States / cities
Chandler, Arizona • Fullerton, California • Long Beach, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Nov 3, 2026, 2:03 PM EST
Active, not recruiting Phase 4 Interventional

VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease

NCT06249165
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
Inclisiran
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
23
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Nov 3, 2026, 2:03 PM EST
Completed Not applicable Interventional

Simplified Drug Regimens for HIV Patients in ACTG 388 or Patients Who Responded to A First Potent Combination Regimen

NCT00014937
View directory record Official record
Conditions
HIV Infections
Interventions
lopinavir/ritonavir, lamivudine/zidovudine, efavirenz, lamivudine, stavudine, zidovudine, didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
32
States / cities
Los Angeles, California • Denver, Colorado • Farmington, Connecticut + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2013 · Synced Nov 3, 2026, 2:03 PM EST
Active, not recruiting Phase 3 Interventional

Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis

NCT05047172
View directory record Official record
Conditions
Intracranial Arteriosclerosis, Stroke
Interventions
Ticagrelor + Aspirin, Rivaroxaban + Aspirin, Clopidogrel + Aspirin, Risk Factor Management
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
30 Years and older
Enrollment
1,683 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
114
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 89 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 3, 2026, 2:03 PM EST
Terminated No phase listed Observational

Quality of Life Assessment of Patients Receiving Treatment for Esophageal Cancer [Companion to CALGB-9781]

NCT00003381
View directory record Official record
Conditions
Esophageal Cancer
Interventions
Not listed
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
44
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2016 · Synced Nov 3, 2026, 2:03 PM EST
Completed Phase 2 Interventional Results available

Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis

NCT02244606
View directory record Official record
Conditions
Mycoses, Candidiasis, Invasive, Candidemia
Interventions
SCY-078, Fluconazole, Micafungin
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
24
States / cities
Birmingham, Alabama • Sacramento, California • Aurora, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Nov 3, 2026, 2:03 PM EST
Active, not recruiting Phase 1Phase 2 Interventional

ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC

NCT05682443
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
ONC-392 low, ONC-392 high, lutetium Lu 177 vipivotide tetraxetan
Drug
Lead sponsor
OncoC4, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
23
States / cities
Sacramento, California • Aurora, Colorado • Tampa, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Nov 3, 2026, 2:03 PM EST
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine

NCT02867709
View directory record Official record
Conditions
Migraine, With or Without Aura
Interventions
Ubrogepant, Placebo-matching Ubrogepant
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,686 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
109
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 91 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Nov 3, 2026, 2:03 PM EST
Completed Not applicable Interventional Results available

Integrated Services for Pain: Interventions to Reduce Pain Effectively

NCT03454555
View directory record Official record
Conditions
Chronic Pain
Interventions
Shared Decision Making, Motivational Interviewing and Cognitive Behavioral Therapy for Chronic Pain
Behavioral
Lead sponsor
RTI International
Other
Eligibility
18 Years to 85 Years
Enrollment
543 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
3
States / cities
Chapel Hill, North Carolina • Durham, North Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Nov 3, 2026, 2:03 PM EST
Completed No phase listed Observational Accepts healthy volunteers

A Blood Test to Look at Cells of the Immune System in Healthy Children

NCT00001109
View directory record Official record
Conditions
HIV Infections, HIV Seronegativity
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 18 Years
Enrollment
630 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
42
States / cities
Birmingham, Alabama • Mobile, Alabama • La Jolla, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2008 · Synced Nov 3, 2026, 2:03 PM EST
Completed Phase 3 Interventional Results available

ATLAS: Ambulatory Treatments for Leakage Associated With Stress

NCT00270998
View directory record Official record
Conditions
Stress Urinary Incontinence, Urinary Incontinence
Interventions
Behavioral Therapy, Intravaginal Pessary, Pessary combined with behavioral therapy
Behavioral · Device
Lead sponsor
NICHD Pelvic Floor Disorders Network
Network
Eligibility
21 Years and older · Female only
Enrollment
445 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
8
States / cities
Birmingham, Alabama • La Jolla, California • Maywood, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated May 30, 2018 · Synced Nov 3, 2026, 2:03 PM EST
Completed Phase 3 Interventional

Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus

NCT00035984
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
AC2993, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
16 Years to 75 Years
Enrollment
734 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
100
States / cities
Anniston, Alabama • Birmingham, Alabama • Montgomery, Alabama + 82 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2015 · Synced Nov 3, 2026, 2:03 PM EST
Terminated Phase 3 Interventional Results available

Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy

NCT02927249
View directory record Official record
Conditions
Node Positive HER2 Negative Breast Cancer
Interventions
Placebo, Aspirin
Other · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 69 Years
Enrollment
3,021 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1426
States / cities
Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 902 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Nov 3, 2026, 2:03 PM EST
Completed Phase 2 Interventional Results available

Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer

NCT00577122
View directory record Official record
Conditions
Estrogen Receptor-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions
Medroxyprogesterone progesterone acetate (MPA), Medroxyprogesterone with Cyclophosphamide + Methotrexate
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
7
States / cities
Birmingham, Alabama • San Francisco, California • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Nov 3, 2026, 2:03 PM EST
Completed Phase 2 Interventional

Paclitaxel in Treating Women With Recurrent Solid Tumors

NCT00003130
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
paclitaxel
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2006
U.S. locations
34
States / cities
La Jolla, California • San Francisco, California • Wilmington, Delaware + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2016 · Synced Nov 3, 2026, 2:03 PM EST
Completed No phase listed Observational

A Rapid Test for Acute Respiratory Illness

NCT03192072
View directory record Official record
Conditions
Respiratory Tract Infection Acute, Transcriptome, Virus Disease, Bacterial Infections
Interventions
Host Gene Expression
Diagnostic Test
Lead sponsor
Duke University
Other
Eligibility
2 Years and older
Enrollment
783 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
10
States / cities
Davis, California • Boston, Massachusetts • Newton, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated May 27, 2020 · Synced Nov 3, 2026, 2:03 PM EST
Recruiting Phase 3 Interventional

A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

NCT06722235
View directory record Official record
Conditions
Immune Thrombocytopenic Purpura (ITP)
Interventions
Mezagitamab, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
25
States / cities
Hot Springs, Arkansas • Los Angeles, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Nov 3, 2026, 2:03 PM EST
Completed Phase 3 Interventional Results available

Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants

NCT03631732
View directory record Official record
Conditions
HIV-1 Infection
Interventions
B/F/TAF, NRTIs, Third Agent
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
82
States / cities
Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 53 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Nov 3, 2026, 2:03 PM EST
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial

NCT01222247
View directory record Official record
Conditions
Pregnancy, Respiratory Distress Syndrome, Pregnancy Outcomes, Preterm Birth
Interventions
Betamethasone, Placebo
Drug
Lead sponsor
The George Washington University Biostatistics Center
Other
Eligibility
Female only
Enrollment
2,831 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2022
U.S. locations
17
States / cities
Birmingham, Alabama • Stanford, California • Denver, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2023 · Synced Nov 3, 2026, 2:03 PM EST
Completed No phase listed Observational

The Effects of Combination Anti-HIV Medication on Human Papillomavirus (HPV) in HIV-Infected Women

NCT00006444
View directory record Official record
Conditions
HIV Infections, Papilloma
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older · Female only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
49
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2013 · Synced Nov 3, 2026, 2:03 PM EST